Yvonne Brandberg's Group

Research with focus in psycho-oncology, i.e. behavioral aspects of cancer prevention, psychosocial reactions to cancer treatment as well as prevention in high-risk groups, effects of cancer treatment, satisfaction and quality of life in clinical trials, development of questionnaires.

Group members

Yvonne Brandberg, Psychologist, Professor, Group leader
Hemming Johansson, BA, Statistician
Mia Bergenmar, Professor Sophiahemmets högskola, Nurse
Anna Kullberg, PhD, Specialist nurse, Nursing development manager
Lucy Bai, MD, PhD


Lucy Bai
Long-term follow-up after risk-reducing mastectomy and immediate breast reconstruction – from a patient, partner and 3D perspective. Karolinska Institutet 2021

Marie Koitsalu
Individualized prostate cancer testing: men's views on participation
Karolinska Institutet 2020

Anna Kullberg
Person-centered shift handovers in oncological inpatient care
Karolinska Institutet 2019

Khairul Majumder
Radiotherapy in prostate cancer: information, quality of life and prostate volume
Karolinska Institutet 2016

Mia Bergenmar
Cutaneous malignant melanoma aspects on prevention.
Karolinska Institutet 2001

Helena Michelson
Long term health-related quality of life among women with high-risk breast cancer receiving adjuvant high-dose chemotherapy : A comparison with the normal population
Karolinska Institutet 2002

Richard Bränström
Skin cancer prevention : Behaviours related to sun exposure and early detection
Karolinska Institutet 2003
Abstract and thesis

Thomas Wahlgren
High dose rate brachytherapy boost for localized prostate cancer : Clinical and patient-reported outcomes
Karolinska Institutet 2006
Abstract and thesis

Selected publications

Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Omran M, Johansson H, Lundgren C, Silander G, Stenmark-Askmalm M, Loman N, Baan A, Adra J, Kuchinskaya E, Blomqvist L, Tham E, Bajalica-Lagercrantz S, Brandberg Y,
Cancer 2023 Mar;129(6):946-955

High levels of health-related quality of life five years after curative treatment of prostate cancer with HDR-brachytherapy and external beam radiation.
Hjälm-Eriksson M, Ullén A, Nilsson S, Johansson H, Nilsson J, Castellanos E, Brandberg Y
Acta Oncol 2022 Oct;61(10):1179-1185

Clinical assessment of breast symmetry and aesthetic outcome: can 3D imaging be the gold standard?
Bai L, Lundström O, Johansson H, Meybodi F, Arver B, Sandelin K, Wickman M, Brandberg Y
J Plast Surg Hand Surg 2023 ;57(1-6):145-152

Effect of Immediate Implant-Based Breast Reconstruction After Mastectomy With and Without Acellular Dermal Matrix Among Women With Breast Cancer: A Randomized Clinical Trial.
Lohmander F, Lagergren J, Johansson H, Roy PG, Brandberg Y, Frisell J
JAMA Netw Open 2021 Oct;4(10):e2127806

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Hatschek T, Foukakis T, Bjöhle J, Lekberg T, Fredholm H, Elinder E, Bosch A, Pekar G, Lindman H, Schiza A, Einbeigi Z, Adra J, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Agartz S, Azavedo E, Grybäck P, Hellström M, Johansson H, Maes C, Zerdes I, Hartman J, Brandberg Y, Bergh J
JAMA Oncol 2021 Sep;7(9):1360-1367

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects.
Koitsalu M, Eklund M, Adolfsson J, Sprangers MAG, Grönberg H, Brandberg Y
Eur Urol Open Sci 2021 Feb;24():43-51

Moderators of the effect of psychosocial interventions on fatigue in women with breast cancer and men with prostate cancer: Individual patient data meta-analyses.
Abrahams HJG, Knoop H, Schreurs M, Aaronson NK, Jacobsen PB, Newton RU, Courneya KS, Aitken JF, Arving C, Brandberg Y, Chambers SK, Gielissen MFM, Glimelius B, Goedendorp MM, Graves KD, Heiney SP, Horne R, Hunter MS, Johansson B, Northouse LL, Oldenburg HSA, Prins JB, Savard J, van Beurden M, van den Berg SW, Verdonck-de Leeuw IM, Buffart LM
Psychooncology 2020 Nov;29(11):1772-1785

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
Brandberg Y, Johansson H, Hellström M, Gnant M, Möbus V, Greil R, Foukakis T, Bergh J,
Breast Cancer Res Treat 2020 May;181(1):87-96

Improved patient satisfaction 2 years after introducing person-centred handover in an oncological inpatient care setting.
Kullberg A, Sharp L, Johansson H, Brandberg Y, Bergenmar M
J Clin Nurs 2019 Sep;28(17-18):3262-3270